Macrophage migration inhibitory factor (MIF) in the development and progression of pulmonary arterial hypertension

Authors

  • Mohamed Ahmed 1. Neonatal-Perinatal Medicine, Pediatrics Department Cohen Children’s Hospital at New York, Northwell Health System 2 The Center for Heart and Lung Research, The Feinstein Institute for Medical Research, Manhasset, New York, USA 3 School of Medicine, Hofstra University, Hempstead, New York, USA
  • Edmund Miller 2 The Center for Heart and Lung Research, The Feinstein Institute for Medical Research, Manhasset, New York, USA 3 School of Medicine, Hofstra University, Hempstead, New York, USA 4 The Elmezzi Graduate School of Molecular Medicine, Manhasset, New York, USA

DOI:

https://doi.org/10.21542/gcsp.2018.14

Abstract

Macrophage migration inhibitory factor (MIF) has been described as a pro-inflammatory cytokine and regulator of neuro-endocrine function. It plays an important upstream role in the inflammatory cascade by promoting the release of other inflammatory cytokines such as TNF-alpha and IL-6, ultimately triggering a chronic inflammatory immune response. As lungs can synthesize and release MIF, many studies have investigated the potential role of MIF as a biomarker in assessment of patients with pulmonary arterial hypertension (PAH) and using anti-MIFs as a new therapeutic modality for PAH.

Downloads

Published

2018-07-23

Issue

Vol. 2018 No. 2 (2018)

Section

Review articles

License

This is an open access article distributed under the terms of the Creative Commons Attribution license CC BY 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.